Skip to main content

news

 

Clifford Chance has advised the Hong Kong-listed SciClone Pharmaceuticals on an offer to take it private by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).

The transaction was implemented via a scheme of arrangement, which allows for a cash consideration of up to an approximate total of $1.13 billion.

Founded in 2010, GL Capital is an investment firm focusing on buyouts and growth opportunities in China’s healthcare industry.

SciClone is engaged in developing and commercialising a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas, including oncology and severe infection. The company was listed in Hong Kong in March 2021.

The Clifford Chance team was led by partners Christine Xu and Tommy Tam.

 Meanwhile, the Slaughter team was headed by partner Bonita Yu.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Khaitan, SAM, Sidley advise on Torrent Power’s $413 mln QIP

by Nimitt Dixit |

Indian law firm Khaitan & Co has advised Torrent Power on its equity offering of $413 million through a qualified institutional placement of shares. Shardul Amarchand Mangaldas & Co and Sidley Austin advised the bookrunning lead managers on the deal.

Deals

IndusLaw guides Zepto’s $350 mln funding round

by Nimitt Dixit |

IndusLaw has guided Indian quick commerce company Zepto on its latest $350 million funding round led by Motilal Oswal's Private Wealth division.

Deals

9 firms advise on milestone $8.2 bln cross-border insurance deal

by Sarah Wong |

Global law firms Debevoise & Plimpton, Kirkland & Ellis and Herbert Smith Freehills are acting for Bermuda-based insurer Resolution Life on its $8.2 billion sale to Japan’s Nippon Life Insurance, the largest overseas acquisition by a Japanese insurer to date.